Neurocrine Biosciences to Present at Upcoming Investor Conferences in May May 6, 2025 04:01PM
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum Mar 11, 2025 04:01PM
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March Feb 25, 2025 04:01PM
Neurocrine Biosciences (NBIX) Announces $500M Share Buyback Feb 21, 2025 08:00AM
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program Feb 21, 2025 08:00AM
View Older Stories

Feb 6, 2025 04:01PM Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
Jan 30, 2025 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
Jan 28, 2025 08:30AM Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
Jan 27, 2025 04:05PM Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
Jan 23, 2025 04:05PM Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Jan 21, 2025 04:06PM Neurocrine Biosciences (NBIX) Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
Jan 21, 2025 04:05PM Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism
Jan 8, 2025 08:34AM Neurocrine Biosciences (NBIX) Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Jan 8, 2025 08:30AM Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
Jan 6, 2025 04:01PM Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec 20, 2024 08:02AM Neurocrine Biosciences (NBIX) Announces Commercial Availability of CRENESSITY for Children and Adults With Classic Congenital Adrenal Hyperplasia
Dec 20, 2024 08:00AM Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
Dec 16, 2024 11:09AM Neurocrine Biosciences (NBIX) Announces FDA Approval of CRENESSITY (earlier)
Dec 13, 2024 06:55PM Neurocrine Biosciences Announces FDA Approval of CRENESSITY™ (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia
Nov 26, 2024 04:01PM Neurocrine Biosciences to Participate at Investor Conferences in December
Nov 7, 2024 08:30AM Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
Nov 5, 2024 04:01PM Neurocrine Biosciences to Participate at Investor Conferences in November
Nov 4, 2024 08:30AM Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
Nov 4, 2024 08:25AM Neurocrine Biosciences (NBIX) Presents New Data on INGREZZA Capsules
Nov 4, 2024 08:25AM Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
Oct 30, 2024 07:00AM Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
Oct 9, 2024 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
Sep 30, 2024 08:31AM Neurocrine Biosciences (NBIX) Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Sep 30, 2024 08:30AM Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Sep 19, 2024 04:01PM Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Sep 12, 2024 04:05PM Neurocrine Biosciences (NBIX) Provides Update on ERUDITE Phase 2 Data for Luvadaxistat
Sep 12, 2024 04:05PM Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Sep 10, 2024 04:01PM Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
Aug 28, 2024 04:05PM Neurocrine Biosciences to Participate at Investor Conferences in September
Aug 28, 2024 07:00AM Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1117568
Aug 28, 2024 07:00AM Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
Aug 7, 2024 04:01PM Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
Aug 1, 2024 07:00AM Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
Jul 18, 2024 08:38AM Neurocrine Biosciences (NBIX) Launches INGREZZA SPRINKLE Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Jul 18, 2024 08:30AM Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Jul 11, 2024 04:01PM Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Jul 1, 2024 07:30AM Neurocrine Biosciences (NBIX) Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
Jul 1, 2024 07:30AM Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
Jun 3, 2024 08:01AM Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
Jun 3, 2024 07:35AM Neurocrine Biosciences (NBIX) Announces Publication of Primary CAHtalyst Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Jun 3, 2024 07:35AM Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Jun 3, 2024 07:31AM Neurocrine Biosciences (NBIX) Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont
Jun 3, 2024 07:30AM Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
May 29, 2024 04:01PM Neurocrine Biosciences to Participate at Investor Conferences in June
May 28, 2024 04:14PM Neurocrine Biosciences (NBIX) Announces CEO Change
May 28, 2024 04:14PM Neurocrine Biosciences Announces CEO Succession Plan
May 28, 2024 08:30AM Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at
May 21, 2024 04:05PM Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA�
May 14, 2024 08:39AM Neurocrine Biosciences (NBIX) Presented Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
May 14, 2024 08:30AM Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
View Older Stories